SIWA Therapeutics, Inc.

SIWA Therapeutics is a pre-clinical stage company. In animal studies, their lead monoclonal antibody targets and destroys senescent cells, with resultant regeneration of muscle in old (CD1) mice and suppression of lung metastases in (BALBc) mice with 4T1 breast cancer. They are focusing on selecting a disease to take into trials. All work to date has been done by independent CROs.